The predecessor of Xinhua Pharmaceutical was Shandong Xinhua Pharmaceutical Factory established in 1943 in the Jiaodong Anti-Japanese Base Area. The company covers an area of ??nearly 3 million square meters and has more than 5,000 employees. It is a key large-scale pharmaceutical enterprise in my country, the largest production and export base of antipyretic and analgesic drugs in Asia, and an important domestic manufacturer of cardiovascular and cerebrovascular, anti-infective and central nervous system drugs. It has a high corporate status and influence in my country's chemical and pharmaceutical industries. The company is an H-share and A-share listed company, one of the top ten technological innovation enterprises in China's pharmaceutical industry, and one of the top 50 companies in China's pharmaceutical industry. Currently it has 9 holding subsidiaries. The "Xinhua Brand" trademark is a well-known trademark in China and an export brand that the Ministry of Commerce focuses on cultivating and developing.
At present, the company's annual output of chemical raw materials exceeds 25,000 tons. It is the world's largest manufacturer of metamizole, ibuprofen, aspirin, caffeine, levodopa and other drugs. It has ethoxy It has 10 exclusive varieties of APIs, including Benisamide, and 8 leading varieties of APIs, ranking first in market share in the country. The annual production capacity of preparations is 8 billion tablets, 300 million injections, and 200 million capsules. Since the beginning of its establishment, the company has always adhered to technology first and quality first, and adheres to the quality concept of "product quality is related to the life of the enterprise, and drug quality is related to the life of people". It strictly controls the quality in production and strives for excellence. The company is the first pharmaceutical and chemical enterprise in China to pass ISO9001, ISO14001, and ISO10012 certifications. All active pharmaceutical ingredients and preparations and dosage forms in production have passed GMP certification. Eight products including theophylline and ibuprofen have passed the U.S. FDA certification. Ten products including theophylline and aspirin have obtained European COS certificates, and caffeine products have passed social responsibility certification, environmental certification for American users, and China Food Safety System (HACCP) certification. At the same time, multiple products have been registered in Russia, India and other countries. The main technical and economic indicators of most leading varieties are in the leading position in the country and are higher than domestic and international certification standards.
The company has a relatively complete scientific research and development system. It is a national high-tech enterprise and a key high-tech enterprise of the National Torch Plan. It has the first batch of national enterprise technology centers and postdoctoral workstations, the first industry-university-research institute in the same industry in China. model, carried out in-depth cooperation with more than 50 scientific research institutions and achieved several scientific research results. Currently, it has 7 national first-class new drug registration numbers and 106 authorized patents.
After more than 60 years of development, the company has built four major production parks: the main factory, Xinhua International Pharmaceutical Industrial Park East Park, West Park, and New Park, forming chemical raw materials, pharmaceutical preparations, pharmaceutical chemical intermediates, A reasonable layout in which the four major sectors of the pharmaceutical business go hand in hand. In the future, the company will adhere to the scientific development concept to guide the overall situation, rely on the four major parks and four major sectors, use independent innovation as the driving force, use structural optimization and upgrading as the starting point, leading products as the leader, and acquisition and expansion of the industrial chain as the development strategy. . Focus on pharmaceuticals, focus on the main business, and do a good job in the auxiliary business - use real estate to feed back the development of the main pharmaceutical business, make APIs and pharmaceutical chemical intermediates more refined, and highlight the development ideas of making pharmaceuticals. Unswervingly follow the path of scientific development, harmonious development, and international development, practice internal skills, expand markets, adjust structures, increase efficiency, achieve good and rapid development, and make new and greater contributions to the development of my country's pharmaceutical industry!
Company environmental policy:
Our company is a large-scale enterprise with chemical synthesis of raw materials and pharmaceutical preparations as its leading products. With the mission of "protecting health and benefiting society", we follow the "quality We adhere to the core values ??of "supremacy and scientific development" and adhere to the path of sustainable development in harmony with the environment.
Environmental protection is the lifeline of Xinhua’s survival and development.
To this end, we commit to:
Comply with applicable laws, regulations and other relevant requirements of the company, continuously improve the awareness and quality of all employees, and enhance the ability to fulfill environmental protection obligations.
We will continue to apply the environmental strategy of source prevention in product design, manufacturing and services, constantly adjust product structure, improve processes and equipment, reduce raw material consumption, promote resource and energy recycling, and reduce pollutant emissions. .
Develop feasible environmental target indicators and review them regularly, continuously improve the environmental management system, and continuously improve environmental performance. Actively cooperate with all relevant parties and consciously accept public supervision